Wedbush Reiterates Outperform Rating for Aerovate Therapeutics (NASDAQ:AVTE)

Wedbush restated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a $41.00 price target on the stock. AVTE has been the subject of a number of other reports. Wells Fargo & Company reissued an overweight rating and […]

Related Keywords

United States ,Georgea Eldridge ,Hunter Gillies ,Eventide Asset Management ,Jefferies Financial Group ,Ikarian Capital ,Nasdaq ,Aerovate Therapeutics Inc ,Wells Fargo Company ,Vanguard Group Inc ,Alps Advisors Inc ,Aerovate Therapeutics ,Free Report ,Financial Group ,Therapeutics Stock Down ,Get Free Report ,Asset Management ,Point Capital ,Alps Advisors ,Aerovate Therapeutics Daily ,